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Background: Trypanosoma cruzi is the etiological agent of Chagas’ disease that is an endemic disease in Latin
America and affects about 8 million people. This parasite belongs to the Trypanosomatidae family which contains a
single mitochondrion with an enlarged region, named kinetoplast that harbors the mitochondrial DNA (kDNA). The
kinetoplast and the nucleus present a great variety of essential enzymes involved in DNA replication and topology,
including DNA topoisomerases. Such enzymes are considered to be promising molecular targets for cancer
treatment and for antiparasitic chemotherapy. In this work, the proliferation and ultrastructure of T. cruzi
epimastigotes were evaluated after treatment with eukaryotic topoisomerase I inhibitors, such as topotecan and
irinotecan, as well as with dual inhibitors (compounds that block eukaryotic topoisomerase I and topoisomerase II
activities), such as baicalein, luteolin and evodiamine. Previous studies have shown that such inhibitors were able to
block the growth of tumor cells, however most of them have never been tested on trypanosomatids.
Results: Considering the effects of topoisomerase I inhibitors, our results showed that topotecan decreased cell
proliferation and caused unpacking of nuclear heterochromatin, however none of these alterations were observed
after treatment with irinotecan. The dual inhibitors baicalein and evodiamine decreased cell growth; however the
nuclear and kinetoplast ultrastructures were not affected.
Conclusions: Taken together, our data showed that camptothecin is more efficient than its derivatives in
decreasing T. cruzi proliferation. Furthermore, we conclude that drugs pertaining to a certain class of
topoisomerase inhibitors may present different efficiencies as chemotherapeutical agents.
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UltrastructureIntroduction
The Trypanosomatidae family comprises protozoa of
medical and veterinary importance. This group includes
species that are the etiological agents of numerous human
diseases, such as Chagas’ disease (caused by Trypanosoma
cruzi), African sleeping sickness (caused by Trypanosoma
brucei), and leishmaniasis (caused by Leishmania spp).
Chagas’ disease was discovered in 1909 and nowadays* Correspondence: motta@biof.ufrj.br
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unless otherwise stated.affects about 8 million people in Latin America and new
cases are being reported in non-endemic areas due to emi-
grations [1].
T. cruzi is a flagellated protozoan and like other trypano-
somatids presents a single mitochondrion with an enlarged
region, termed kinetoplast, which contains the mitochon-
drial DNA (kDNA). T. cruzi also has a single spherical nu-
cleus presenting a condensed heterochromatin next to the
nuclear envelope and around the nucleolus [2-6]. Since the
nucleus and the kinetoplast are cellular compartments that
contain DNA, their structural organization depends on en-
zymes such as topoisomerases, that play a key role during
replication, transcription, recombination and repair [7-9].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Type I attaches to DNA and breaks one strand of the
double helix that can rotate around its own axis to revert
supercoiling. On the other hand, type II binds to a DNA
double strand and makes a gate allowing a second DNA
double helix pass [10].
Several topoisomerase inhibitors have been developed
based on different types of these enzymes that have been
considered as potent targets in chemotherapeutic stud-
ies, especially with tumor cells. Topo I inhibitors, such
as camptothecin, form a ternary complex, since they can
trap the enzyme and DNA together [11-14]. Topo II in-
hibitors, such as mitoxantrone and etoposide, bind to
the enzyme preventing the re-ligation of the DNA double
strand. Furthermore, some inhibitors share character-
istics of the two groups described above and target
both topo I and topo II, thereby being called dual in-
hibitors [15].
Many topoisomerase inhibitors are natural products
extracted from plants, such as camptothecin, isolated
from Camptotheca accuminata, and several alkaloids,
such as evodiamine, isolated from Evodia rutaecarpa [16].
Topotecan and irinotecan are camptothecin derivatives
that have been used for ovarian and colorectal cancer
treatments, respectively. These inhibitors target topo I and
bind to DNA, forming a cleavable complex. The collision
between this ternary complex and a replication fork gener-
ates DNA double-strand breaks, which may be related to
the S-phase cytotoxicity, the G2/M cell cycle arrest and
DNA damage that activates repair proteins [14].
Baicalein, luteolin and evodiamine are topoisomerase
dual inhibitors. Baicalein is an alkaloid isolated from
Scutellaria baicalensis used in the treatment of hyperten-
sion, atherosclerosis, dysentery and inflammatory diseases
[16]. Luteolin is a flavonoid, a group of natural com-
pounds with therapeutic properties that causes apoptosis
in promastigote forms of L. donovani [17-19]. Evodiamine
is an alkaloid extracted from Evodia rutecarpa used as an
anticancer, anti-inflammatory and antiobesity agent [20].
This compound was initially classified as a topo I inhibitor,
but then it was proposed that evodiamine could also bind
to topoisomerase II [21].
In the present work, we evaluated the effects of the
eukaryotic topoisomerase I inhibitors, topotecan and iri-
notecan, and the eukaryotic dual inhibitors baicalein,
luteolin and evodiamine on the epimastigote forms of




T. cruzi epimastigote forms were grown at 28°C for 24 h
in liver infusion tryptose (LIT) medium [22] supplemented
with 10% fetal calf serum.Drug treatment
Topotecan, irinotecan, baicalein, luteolin and evodiamine
were purchased from Sigma Aldrich and diluted in di-
methyl sulfoxide (DMSO) at 5 mM and 30 mM. The drug
was added to the culture medium after 24 h of initial
growth, which corresponds to the exponential phase. Drug
concentrations were used as follows: 1, 5, 10, 50, 100, 200
and 300 μM. Every 24 h cells were collected and counted
in a Neubauer chamber during the 96 h of cultivation.
Paired t-tests were applied to the results using 95% confi-
dence interval (GraphPad Prism version 5.00 for windows;
GraphPad Software Inc., San Diego, CA).
Cell viability was performed using the MTS/PMS col-
orimetric method, which is based on dehydrogenase ac-
tivity and the conversion of MTS into formazan, that
indicates the number of metabolically active cells [23].
Parasites were incubated with MTS/PMS solution for
4 h and formaldehyde 0.4% was used as negative control.
The percentage of viable protozoa was obtained through a
spectrofluorimeter (Molecular Devices Microplate Reader
(SpectraMax M2/M2e, Molecular Devices) using a 490 nm
wavelength. MTS/PMS is a colorimetric assay, based on
dehydrogenase activity and the conversion of MTS into
formazan, that indicates the number of metabolically active
cells.
Transmission electron microscopy
Protozoa were fixed in 2.5% glutaraldehyde diluted in 0.1 M
cacodylate buffer (pH 7.2) for 1 h at room temperature and
were washed in the same buffer. Cells were post-fixed for
1 h in 0.1 M cacodylate buffer containing 1% OsO4 and
0.8% potassium ferricyanide. Protozoa were washed in the
same buffer and were dehydrated in a graded series of
acetone and embedded in Epon (Electron Microscopy
Sciences, Hatfield, PA). Ultrathin sections were stained
with uranyl acetate and lead citrate and were observed
using a Zeiss 900 transmission electron microscope (Zeiss,
Oberkochen, Germany).
Results
Regarding topoisomerase I inhibitors, cell proliferation was
not significantly affected by topotecan after treatment with
50 μM for 72 h, while up to 300 μM reduced cell prolifera-
tion by approximately 3 fold in relation to the control
cells was observed (Figure 1a), resulting in IC50 value of
110 μM. It is interesting to point out that induction of cell
growth inhibition was noted after 48 h of treatment. Fur-
thermore, this compound induced cell viability decay in a
dose dependent manner, which corresponds to 20% after
protozoa cultivation in medium containing 200 or 300 μM
topotecan for 72 h (Figure 1b). On the other hand, irinote-
can did not promote growth impairment with any of the
concentrations tested (Figure 1c). Also cell viability was
not affected (data not shown for Additional file 1).
Figure 1 The effects of topoisomerase I inhibitors on T. cruzi epimastigotes after 72 h of treatment. (a) Topotecan affected cell proliferation
especially after using higher drug concentrations. (b) Cell viability of T. cruzi treated with topotecan was reduced in a dose-dependent way after
treatment for 48 h. (c) Irinotecan did not cause a significant growth inhibition even after treatment for 72 h. The asterisks indicate drug
addition to the culture medium. Data are the average of three independent experiments. DMSO, dimethyl sulfoxide.
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ultrastructural modifications caused by these inhibitors. After
treatment with lower concentrations, T. cruzi ultrastructurewas similar to control cells (Figure 2a). However protozoa
cultivation with 300 μM topotecan for 72 h led to an
unpacking of the nuclear heterochromatin around the
Figure 2 The effects of topoisomerase I inhibitors on the
ultrastructure of T. cruzi epimastigotes. (a) Control parasite,
showing the typical organization of the nucleus containing the
condensed heterochromatin (ht) around the nucleolus (nu), the bar
shape kinetoplast (k) and the mitochondrion (m). (b) When T. cruzi
was treated with 300 μM topotecan for 72 h, the cells presented an
unpacking of nuclear heterochromatin and mitochondrial swelling
(m), especially in the kinetoplast (k) region. (c) T. cruzi treated with
300 μM of irinotecan for 72 h, showing a slight unpacking of nuclear
heterochromatin (ht). gc, Golgi complex; f, flagellum. (A) and (B)
Bars = 2 μm. (C) Bars = 1 μm.
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chondrial swelling was also observed, especially in the kin-
etoplast region; however the kDNA arrangement was not
affected (Figure 2b). Like the lack of effect in cell prolifera-
tion, irinotecan did not cause any significant changes in the
cell ultrastructure. The main effect observed was a slight
unpacking of heterochromatin (Figure 2c) and mitochon-
drial swelling, but with less intensity when compared
to protozoa treated with topotecan.
The dual inhibitor baicalein affected cell proliferation
in a dose-dependent manner (Figure 3a), resulting in an
IC50 of 62.83 μM after 72 h. Treatment with 300 μM
baicalein for 24 h promoted a decrease of approximately
3 fold in parasite number and this difference increased to
about 24 fold after 72 h (Figure 3a). Similar results were
observed in cells treated with 200 μM baicalein, whereas
the concentration of 100 μM reduced protozoa prolifera-
tion, but did not promote cell growth arrest. Luteolin was
not able to inhibit protozoa growth significantly even after
treatment with 300 μM for 72 h (Figure 3b). Evodiamine
only promoted an expressive decay in cell proliferation
after using concentrations equal or superior to 100 μM,
when it was possible to observe a dose-dependent de-
crease in growth (Figure 3c), which is lower when com-
pared to that caused by baicalein (Figure 3a). Regarding
cell viability, after comparing the effect of these topoisom-
erase dual inhibitors, it is possible to conclude that baica-
lein was the most potent drug. This compound reduced
the percentage of viable protozoa to approximately 30%
after treatment with 200 μM for 24 h and this value was
inferior to 20% after using 200 μM for 72 h (Figure 4a).
The effect of evodiamine on cell viability was less intense
than that observed for baicalein, but interestingly it was
more pronounced in cells treated for 24 h (Figure 4b).
Luteolin did not interfere in cell viability (data not shown
for Additional file 2).
In terms of T. cruzi ultrastructure, the parasites treated
with dual inhibitors did not present alterations when com-
pared to the control cells. These compounds did not lead to
modifications in the kDNA topology or in the heterochro-
matin organization, as was observed after treatment with
topo I inhibitors (data not shown for Additional file 3).
Table 1 summarizes data obtained in this work showing
the IC50 values and the main ultrastructural alterations
caused by topoisomerase I and dual inhibitors to the
T. cruzi epimastigotes.
Discussion
In the present work, the effects of different topoisomer-
ase inhibitors were evaluated considering T. cruzi prolif-
eration and ultrastructure. Irinotecan and topotecan are
derivatives of camptothecin, thus they act by binding to
DNA and to topoisomerase I by forming a ternary com-
plex, referred to as a cleavable complex. These compounds
Figure 3 The effects of dual inhibitors on T. cruzi epimastigotes after 72 h of treatment. (a) Baicalein considerably reduced protozoa
proliferation in a dose-dependent manner. (b) Luteolin did not promote growth impairment. (c) Evodiamine caused a reduction of parasite
proliferation, but values were very similar with different drug concentrations. The asterisks indicate drug addition to the culture medium.
Data are the average of three independent experiments. DMSO, dimethyl sulfoxide.
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ing to cell cycle blockade, activation of DNA repair and
apoptosis [24].Here, we observed that topotecan promoted a moderate
effect on cell proliferation, whereas irinotecan did not affect
protozoa growth. These results revealed that such inhibitors
Figure 4 The effects of baicalein and evodiamine on T. cruzi viability after 72 h of treatment. (a) The number of viable cells was strongly
reduced after treatment with baicalein. (b) Evodiamine caused a lower reduction of cell viability when compared to baicalein. Data are the
average of three independent experiments. DMSO, dimethyl sulfoxide.
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pared to camptothecin, the precursor compound, which
presented IC50 values of 2.08 μM. The typical ultrastructural
alterations, such as the unpacking of nuclear heterochroma-
tin, promoted by topoisomerase I inhibitors were observed
in cells treated with topotecan; however such modifications
were only noticed after using high drug concentrations [25].
As described previously, topotecan and irinotecan were
able to inhibit tumor cell proliferation, and were more
effective and less toxic than camptothecin [26,27]. Such
effects have also been reported on T. brucei and on
Leishmania infantum promastigotes. In both these trypa-
nosomatid species topotecan presented more efficacy than
irinotecan, especially in T. brucei. The IC50 values corres-
pond to 1.23 μM for topotecan and 21.5 μM for irinotecan
on T. brucei, whereas values are equivalent to 10.86 μM for
topotecan and superior to 200 μM for irinotecan on
L. infantum [28,29]. A previous work also showed that
camptothecin was cytotoxic to T. brucei and L. donovani,
with IC50 values ranging from 1 to 3 μM [30].
Baicalein was the most effective compound against T.
cruzi proliferation and viability considering all the inhibi-
tors evaluated in this study. The treatment of Leishmania
promastigotes with concentrations inferior to 15 μM of
baicalein for 24 h was previously reported to reduce para-
site growth up to 89% [31]. Furthermore, published data
demonstrated that this drug inhibited tumor cell growth
in vitro and in vivo and presented low toxicity [16,32].
Baicalein, evodiamine and luteolin are all classified as
dual inhibitors of topoisomerase; but the latter compoundTable 1 Effects of topoisomerase I and dual inhibitors on Tryp
Drugs Target IC50 (μM)
Topotecan Eukaryotic Topo I Inhibitor 110
Irinotecan Eukaryotic Topo I Inhibitor > 300
Baicalein Eukaryotic Dual Inhibitor 62,83
Luteolin Eukaryotic Dual Inhibitor > 300
Evodiamine Eukaryotic Dual Inhibitor 90,73did not promote any effect on T. cruzi cell proliferation.
However, luteolin inhibits the growth of several cancer
cell lines, blocking the cell cycle in the G1 phase [33]. In
Leishmania, this inhibitor was also able to induce cell cycle
arrest and apoptosis [18]. In this work, evodiamine pro-
moted a slight inhibition of T. cruzi proliferation (IC50
90 μM) when compared to baicalein (IC50 62.83), however
this compound has presented efficacy against different can-
cer cell lines [20]. Dual inhibitors target topoisomerases I
and II, thus it was expected that such compounds could
present high efficiency in blocking cell proliferation and
also promoting ultrastructural changes in the nucleus and
kinetoplast; however these effects were not observed in
T. cruzi after treatment with these inhibitors.
Conclusions
DNA topoisomerases represent an interesting target for
anti-parasitic chemotherapy, since their inhibition inter-
feres with the replicative process, which can lead to
parasite death. In this work, we showed that compounds
pertaining to the same topoisomerase inhibitor class had
different effects on T. cruzi proliferation and ultrastruc-
ture. All inhibitors evaluated in this work are efficient
for cancer therapy and sometimes blocked trypanosoma-
tid growth, however their effects on T. cruzi proliferation
and ultrastructure had never been investigated. Thus, we
considered that they could be promissory agents in che-
motherapeutic studies against T. cruzi, however these
compounds presented considerably high IC50 values.
The low effects observed in this parasite can be relatedanosoma cruzi after 72 h of treatment
Ultrastructural effects
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protozoan topoisomerase domains, affinity for the target
enzyme, cell membrane permeability and cell resistance,
including mechanisms of drug efflux. Our results reinforce
the idea that it is necessary to develop new compounds
that may be successfully used in the therapy against
neglected diseases.
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Additional file 1: Cell viability of T. cruzi Y with irinotecan. T. cruzi
viability was not affected after treatment with irinotecan. The number of
treated cells were similar to control parasites.
Additional file 2: Cell viability of T. cruzi Y with luteolin. T. cruzi
viability was not affected after treatment with luteolin.
Additional file 3: The effects of dual inhibitors on the ultrastructure
of T. cruzi epimastigotes. (A) T. cruzi treated with 50 μM of baicalein for
72 h. (B) T. cruzi treated with 300 μM of luteolin for 72 h. (C) T. cruzi treated
with 300 μM of evodiamine for 72 h. Note that the nucleus and the
kinetoplast preserved their typical organization. Bars = 1 μm. K, kinetoplast;
ht, heterochromatin; nu, nucleolus; m, mitochondrion; f, flagellum.
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